Literature DB >> 19820436

Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis.

Jarmila Szilasiová1, Zuzana Gdovinová, Jagienka Jautová, Janette Baloghová, Marta Ficová, Peter Bohus.   

Abstract

We report a 38-year-old woman with relapsing-remitting multiple sclerosis, treated with subcutaneous injections of interferon beta (IFN-beta)-1b every other day. Disseminated cutaneous lesions were observed after 3 injections. These symptoms reappeared after drug readministration. The histopathological examination of the skin specimens confirmed nonspecific cutaneous lymphocytic vasculitis. The patient's outcome was favorable after corticosteroid placement and discontinuing IFN-beta therapy. Isolated lymphocytic cutaneous vasculitis linked to IFN-beta-1b therapy is suspected as a new association.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19820436     DOI： 10.1097/WNF.0b013e3181a2b5fd

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


  5 in total

1.  Aicardi goutières syndrome is associated with pulmonary hypertension.

Authors:  Laura A Adang; David B Frank; Ahmed Gilani; Asako Takanohashi; Nicole Ulrick; Abigail Collins; Zachary Cross; Csaba Galambos; Guy Helman; Usama Kanaan; Stephanie Keller; Dawn Simon; Omar Sherbini; Brian D Hanna; Adeline L Vanderver
Journal:  Mol Genet Metab       Date:  2018-09-07       Impact factor: 4.797

2.  Activated STING in a vascular and pulmonary syndrome.

Authors:  Y Liu; A A Jesus; B Marrero; Z Deng; M Boehm; A S Paller; D Yang; S E Ramsey; G A Montealegre Sanchez; K Tenbrock; H Wittkowski; O Y Jones; H S Kuehn; C-C R Lee; M A DiMattia; E W Cowen; B Gonzalez; I Palmer; J J DiGiovanna; A Biancotto; H Kim; W L Tsai; A M Trier; Y Huang; D L Stone; S Hill; H J Kim; C St Hilaire; S Gurprasad; N Plass; D Chapelle; I Horkayne-Szakaly; D Foell; A Barysenka; F Candotti; S M Holland; J D Hughes; H Mehmet; A C Issekutz; M Raffeld; J McElwee; J R Fontana; C P Minniti; S Moir; D L Kastner; M Gadina; A C Steven; P T Wingfield; S R Brooks; S D Rosenzweig; T A Fleisher; R Goldbach-Mansky
Journal:  N Engl J Med       Date:  2014-07-16       Impact factor: 91.245

3.  Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiency.

Authors:  Stefano Vavassori; Janet Chou; Laura Eva Faletti; Veronika Haunerdinger; Lennart Opitz; Pascal Joset; Christopher J Fraser; Seraina Prader; Xianfei Gao; Luise A Schuch; Matias Wagner; Julia Hoefele; Maria Elena Maccari; Ying Zhu; George Elakis; Michael T Gabbett; Maria Forstner; Heymut Omran; Thomas Kaiser; Christina Kessler; Heike Olbrich; Patrick Frosk; Abduarahman Almutairi; Craig D Platt; Megan Elkins; Sabrina Weeks; Tamar Rubin; Raquel Planas; Tommaso Marchetti; Danil Koovely; Verena Klämbt; Neveen A Soliman; Sandra von Hardenberg; Christian Klemann; Ulrich Baumann; Dominic Lenz; Andreas Klein-Franke; Martin Schwemmle; Michael Huber; Ekkehard Sturm; Steffen Hartleif; Karsten Häffner; Charlotte Gimpel; Barbara Brotschi; Guido Laube; Tayfun Güngör; Michael F Buckley; Raimund Kottke; Christian Staufner; Friedhelm Hildebrandt; Simone Reu-Hofer; Solange Moll; Achim Weber; Hundeep Kaur; Stephan Ehl; Sebastian Hiller; Raif Geha; Tony Roscioli; Matthias Griese; Jana Pachlopnik Schmid
Journal:  J Allergy Clin Immunol       Date:  2021-04-17       Impact factor: 10.793

Review 4.  Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.

Authors:  Meghna Jani; William G Dixon; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580

Review 5.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.